Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Evaluate's commercial intelligence on the pharmaceutical, biotechnology, and medical device industries is consistently referenced by leading business and industry publications such as the Financial Times, Wall Street Journal, and Nature.
Download our latest Media Kit for a forward-looking view of top companies, products, and more to support your editorial content.
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
The new lineup is projected to generate $8.3 billion in sales this year, according to EvaluatePharma. For the first time, Pfizer in 2019 expects oncology products to…
An analysis by Evaluate Pharma showed Celgene spent $3.5 billion in cash payments to smaller biotechs to cement partnership deals, 50 percent more than the next biggest…
The stock was still up over 40% at $2.24 by around midday, even though there are plenty of reasons to wait before declaring this trial a success, including missing…